The Everest trial is evaluating the safety and efficacy of the MitraClip device for the treatment of mitral regurgitation (MR). The data analysis was based on 23 patients with moderate-to-severe or severe functional MR (FMR). The data shows that 83% of the 23 FMR patients had successful MR reduction after the MitraClip procedure. Additionally, the majority (74%) of successfully treated FMR patients showed MR reduction to less than or equal to 2+ MR. Importantly, the MR reduction was maintained, with a Kaplan-Meier durability of MR reduction in 89% of patients at one and two years.
Other results, showed that at one year, clinical symptoms improved or stabilized compared to baseline in 92% of successfully treated FMR patients (matched data, n=12). Symptomatic relief was seen in 70% of FMR patients who had a history of heart failure.
Ferolyn Powell, president and CEO of Evalve, said: “The reduction of MR with durable results and improved heart function highlight the potential of the MitraClip device. We believe we are making strides with a new, less-invasive method of valve repair for both functional MR and degenerative MR patients.”